Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Khiron Life Sciences Corp.
  6. News
  7. Summary
    KHRN   CA49374L3065


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Khiron Life Sciences : Vicente Fox, Khiron Board Member and Former President of Mexico, Applauds Mexican Supreme Court's Advancement of Cannabis Laws

06/30/2021 | 09:27am EDT
  • Mexico's Supreme Court has voted to decriminalize adult use cannabis, allowing adults to apply for permits to cultivate and consume their own cannabis
  • Khiron reiterates plans to enter Mexican medical cannabis market in 2021 through previously announced clinic and education strategy
  • Recent regulatory and supply chain advances accelerate the Company's entry into the medical market by several months

TORONTO, June 30, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today reiterates its plans to enter the Mexican medical cannabis market in 2021, following a landmark vote by the Mexican Supreme Court to decriminalize adult use cannabis. The decision of the Supreme Court underscores the political and social commitment to normalize the use of cannabis in Mexico.

Vicente Fox, Khiron Director and former President of Mexico, comments, "I believe Mexico will be the largest legal cannabis market in the world, and with a proven strategy for Latin America and the knowledge and track record to execute, Khiron remains at the forefront of this exciting market. Today's vote by the Supreme Court is an important step forward on the road to full legalization in Mexico."

With extensive experience developing magistral preparations, generating clinical evidence, operating pharmacies, and exporting highly regulated cannabis products, Khiron's experience in Colombia is expected to provide competitive advantages for its entry into Mexico's medical cannabis market. 

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vicente-fox-khiron-board-member-and-former-president-of-mexico-applauds-mexican-supreme-courts-advancement-of-cannabis-laws-301323194.html

SOURCE Khiron Life Sciences Corp.

© Canada Newswire, source Canada Newswire English

09/13KHIRON LIFE SCIENCES : Renews Normal Course Issuer Bid
09/09KHIRON LIFE SCIENCES : Announces Intention to Renew Normal Course Issuer Bid
09/09Khiron Life Sciences Corp. announces an Equity Buyback for 8,955,893 shares, representi..
09/09Khiron Life Sciences Corp. authorizes a Buyback Plan.
08/31KHIRON LIFE SCIENCES : Registers First Medical Cannabis Products in Peru
08/31KHIRON LIFE SCIENCES : Registers its First Two Medical Cannabis Products in Peru, Availabl..
08/31Khiron Registers its First Two Medical Cannabis Products in Peru
08/23KHIRON LIFE SCIENCES : Books Q2 Loss of C$0.03 per Share, Expects Medical Cannabis Revenue..
08/23Khiron Life Sciences Corp. Reports Earnings Results for the Second Quarter Ended June 3..
08/11KHIRON LIFE SCIENCES CORP. : Invitation to the Q3 Virtual Investor Summit
More news
Sales 2021 13,0 M 10,3 M 10,3 M
Net income 2021 -22,2 M -17,5 M -17,5 M
Net Debt 2021 15,0 M 11,8 M 11,8 M
P/E ratio 2021 -1,43x
Yield 2021 -
Capitalization 51,0 M 40,2 M 40,3 M
EV / Sales 2021 5,08x
EV / Sales 2022 2,26x
Nbr of Employees -
Free-Float 94,7%
Duration : Period :
Khiron Life Sciences Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KHIRON LIFE SCIENCES CORP.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,29 CAD
Average target price 0,85 CAD
Spread / Average Target 198%
EPS Revisions
Managers and Directors
┴lvaro F. Torres Chief Executive Officer & Director
Joel Friedman Chief Financial Officer
Chris Naprawa Chairman
Jairo Espinoza Vice President-Medical Affairs
Manuel Buendia Vice President-Operations
Sector and Competitors